Healthtech Startups

Brandon BioCatalyst funds biomedical development opportunities associated with its Member Institutes, offering investments ranging from AU$500,000 to AU$30 million across stages from proof-of-concept to late-stage technologies. It operates an investment process through an Investment Review Committee, with due diligence handled by Brandon Capital.

2 investors

BRC Therapeutics develops and manufactures botanically-derived pharmaceutical products, with expertise spanning drug development and manufacturing for pharmaceutical applications.

2 investors

Brenig Therapeutics is a biotechnology company developing small-molecule therapies for Parkinson's disease and other neurodegenerative disorders, using AI-driven drug discovery. Its pipeline includes BT-267, a brain-penetrant LRRK2 inhibitor, and BT-409, an NLRP3 inflammasome inhibitor.

2 investors

Brick Health operates a network of physical medical facilities that offer diagnostic testing, nursing services, phlebotomy, and point-of-care lab work at fixed transparent prices, enabling virtual care providers to deliver a broader range of medical services to patients.

2 investors

Bridge provides billing and compliance infrastructure for telehealth and healthcare practices, handling insurance logistics and administrative workflows so providers can focus on patient care. The company specializes in healthcare compliance and has received regulatory validation from the Office of Inspector General.

2 investors

Bright Health Group operates a healthcare platform with two segments: NeueCare, which delivers primary care through owned and affiliated clinics serving populations across ACA, Medicare, and Medicaid; and NeueSolutions, which enables independent providers to succeed in value-based care arrangements through financial alignment tools and partnerships with health plans.

2 investors

Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform. The company operates in the immuno-oncology drug development space.

2 investors

BrightHeart develops the B-Right AI Platform, an AI system that analyzes routine prenatal ultrasound images and clips to help clinicians and sonographers detect signs of congenital heart defects and confirm fetal heart scan completeness. The standalone platform is designed for obstetric and fetal screening clinical teams and integrates with existing ultrasound and reporting systems.

2 investors

BrightPay offers No Cost EMI and "pay later" financing for healthcare expenses, letting patients scan a QR code at clinics or hospitals to convert bills into interest-free installment plans over 3 to 12 months. It partners with healthcare facilities and digital health platforms to serve patients in India.

2 investors

BrightSpring Health Services operates complementary home and community-based health services for complex populations requiring specialized or chronic care, including home health, hospice, senior care, and pharmacy management across all 50 U.S. states. The company serves over 400,000 patients and clients with a focus on clinical quality and technology-driven outcomes.

2 investors

Brinter develops 3D bioprinting technology for regenerative implants. The company serves the medical and biotech industries focused on human repair applications.

2 investors

2 investors

Briteseed develops hyperspectral imaging technology integrated into laparoscopic and robotic surgical instruments to provide real-time visualization of critical anatomical structures during surgery. The company produces a suite of surgical tools including energy, stapler, and dissection instruments that display information on existing operating room monitors to improve surgical safety and outcomes.

2 investors

BROND provides provider-reviewed health and wellness products and care plans for men and women focused on energy, sexual health, and longevity support. The company delivers prescription-based treatments with ongoing follow-up, emphasizing performance maintenance and hormone optimization over quick fixes.

2 investors

Brooklyn Health builds objective, sensitive measurement tools for symptoms of neurological and neuropsychiatric disorders, aimed at reducing risk in CNS drug development. It serves the biotech and pharmaceutical sector with a team of clinicians, scientists, engineers, designers, and operators focused on the measurement problem in health.

2 investors

bswift provides an AI-native benefits administration platform paired with expert service and an in-house engagement agency, helping HR teams manage enrollment, employee communications, and benefits engagement. It serves employers across industries, including large organizations, and offers tools such as an AI benefits assistant and personalization engine to increase benefits utilization and contain healthcare costs.

2 investors

Buckeye AI is a stealth-stage company developing an automation platform. The page gives no further detail about the product or its intended customers.

2 investors

Budy is developing an AI employee designed to remember context and carry out assigned work tasks. The product is invite-only and its waitlist has not yet opened.

2 investors

Bugworks Research is a drug discovery company developing small molecule therapeutics, including novel antibacterial agents targeting antimicrobial resistance (AMR) across Gram-negative and Gram-positive infections and next-generation immuno-oncology treatments for hard-to-treat tumors. Its research focuses on affordable oral and intravenous therapies for serious hospital and community infections and cancer.

2 investors

A healthcare technology company combining clinical leadership with logistics expertise to improve healthcare access globally, with particular focus on remote and underserved regions.

2 investors

BullFrog AI develops AI/ML software for drug discovery that harmonizes fragmented biomedical data and analyzes complex multimodal datasets to identify patient subgroups, drug targets, and biomarkers. It serves biopharma and life sciences teams working on clinical trials and translational research.

2 investors

Developing a point-of-care diagnostic assay integrating washing and signal amplification.

2 investors

C the Signs develops AI-powered tools for early cancer detection using real-time data and evidence-based pathways. The platform is designed for healthcare systems and clinicians to improve patient outcomes through earlier diagnosis across all populations.

2 investors

Hyperion Biosystems builds diagnostic devices that use computer vision and physics-based algorithms to improve the sensitivity and specificity of point-of-care and at-home tests. Its products include the HALO platform and Helios, a rapid molecular diagnostic platform combining padlock probe chemistry, isothermal amplification, and optical readout for multiplexed, single-copy detection.

2 investors